PSPengfei She

Pengfei She

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pengfei She has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antimicrobial effects of nifuratel against Staphylococcus epidermidis by targeting proton motive force

    by Pengfei She, Kening Lin, Dan Shu, Yongjun Liu, Di Zhang

    The increasing antimicrobial resistance of Staphylococcus epidermidis, a leading opportunistic pathogen causing device‑related and nosocomial infecti

  • Open Access

    Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against acinetobacter baumannii

    by Pengfei She, Mengna Li, Yiqing Liu, Guanqing Huang, Shaowei Guo, Dan Xiao, Yelan Hong, Lihua Lu, Yong Wu

    Acinetobacter baumannii is an opportunistic pathogenic Gram-negative bacillus and one of the main pathogens causing hospital-acquired infections. It can cause varied types of infection, including m...


  • Open Access

    Cloxiquine exerts bactericidal activity against Enterococcus faecalis through disruption of proton motive force and induction of reactive oxygen species

    by Qi Yang, Yuan Wu, Xueting Wan, Ruixue Yang, Ye Tao, Pengfei She

    The antibiotic resistance of Enterococcus faecalis (E. faecalis) continues to rise and spread globally, posing a severe challenge to clin

  • Open Access

    Antibacterial and Antibiofilm Activity of Closantel Against Staphylococcus epidermidis

    by Wu Pingyun, Wu Yuan, Wu Ruolan, Wan Xueting, Yang Qi, She Pengfei

    Staphylococcus epidermidis is recognized as the major cause of implanted indwelling medical device‐related infections. The ability of S. epidermidis to form biofilms largely increases its resistance to conventional antibiotics, which is the major cause of treatment failure. Therefore, there is a pressing need to discover novel antimicrobials against S. epidermidis biofilms. In this study, Closantel (Clos), an antiparasitic drug, was repurposed to be effective against S. epidermidis planktonic cells with the minimal inhibitory concentration values of 0.25–0.5 μg/mL. Clos exhibited potent biofilm inhibition at ≥ 0.5 μg/mL and achieved effective eradication at ≥ 1 μg/mL. Notably, Clos induced lower resistance in S. epidermidis compared to Rifampicin. Mechanism study indicated that Clos exerted the bactericidal activity mainly through inducing bacterial cell membrane depolarization and further disruption. And the antibiofilm activity of Clos could be partially due to the inhibition of initial adhesion and extracellular polysaccharides production. In addition, CCK‐8 assay showed that Clos at 16 μg/mL had limited cytotoxicity in A2780, HaCaT and 293 T cells. In conclusion, this study demonstrates that Clos, a molecule targeting bacterial cell membranes, exhibits strong antimicrobial and antibiofilm effects in vitro against S. epidermidis . Although, side effects were reported in mammals, developing Clos derivatives could be still an effective therapeutic strategy to treat S. epidermidis ‐related infections.


  • Open Access

    匹维溴铵与苯唑西林联用对表皮葡萄球菌的协同抗菌作用

    by 乐宏 袁, 鹏飞 佘

    表皮葡萄球菌能黏附于医疗器械表面形成高耐药的生物被膜,针对表皮葡萄球菌及其生物被膜的新型抗菌药物研发已成为研究热点。本研究通过药物重新利用,探讨L型钙离子通道阻断剂匹维溴铵(pinaverium bromide,PVB)与苯唑西林(oxacillin,OXA)联合使用对表皮葡萄球菌的抗菌作用。 表皮葡萄球菌临床菌株于2022年1至9月收集于中南大学湘雅三医院检验科。通过微量肉汤稀释实验检测PVB和OXA的最低抑菌浓度(minimal inhibitory concentration,MIC)。棋盘稀释实验和时间-杀菌曲线用于检测PVB和OXA联用的协同抑菌指数和协同杀菌效率。耐药筛选实验用于检测PVB抑制OXA耐药性形成的能力。生物被膜清除实验结合激光共聚焦显微镜观察和持留菌计数实验用于检测PVB与OXA联用对表皮葡萄球菌高耐药性生物被膜和持留菌的抗菌作用。通过透射电镜、活性氧(reactive oxygen species,ROS)定量实验和ATP定量实验探讨PVB的作用机制。 PVB和OXA对表皮葡萄球菌标准菌株RP62A的MIC均为8 μg/mL。棋盘稀释实验显示PVB与OXA联用对表皮葡萄球菌标准菌株RP62A的协同抑菌指数为0.250 0,对临床分离菌株的协同抑菌指数为0.187 5~0.500 0,提示均为协同作用。耐药筛选实验发现PVB不仅不会产生耐药,还能有效抑制OXA产生耐药。1×MIC的PVB和OXA联用时,可使生物被膜的吸光度(A570 nm)从(2.36±0.46)减少到(1.12±0.39) (t=3.504,P=0.02)。通过激光共聚焦显微镜观察可知,PVB和OXA联用还可明显破坏生物被膜的结构,使死亡细菌的比例增加。同时,1×MIC的PVB和OXA作用于持留菌4 h,可使持留菌的总量从lg(7.73±0.21)减少到lg(2.79±0.43)(t=4.143,P=0.014)。此外,PVB联用OXA的协同抗生物被膜效果在临床菌株中得到进一步验证。透射电镜观察发现PVB可使细菌结构明显破坏。OXA与PVB联用可显著诱导细菌产生ROS,使ROS相对荧光强度从(30 000.00±2 000.00)升高到(45 666.67±2 081.67) (t=10.68,Pt=4.932,P=0.003)。 PVB联用OXA对表皮葡萄球菌及其生物被膜和持留菌具有显著的协同抗菌作用,有望成为难治性表皮葡萄球菌生物被膜相关感染的替代药物。

  • Open Access

    Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus

    by Ruolan Wu, Yuan Wu, Pingyun Wu, Huilong Li, Pengfei She

    With the growing antibiotic resistance in Staphylococcus aureus, it is imperative to develop innovative therapeutic strategies against new targets to reduce selective survival pressures and incidence of resistance. In S. aureus, interbacterial communication relies on a quorum sensing system that regulates gene expression and physiological activities. Here, we identified that Visomitin, an antioxidant small molecule, exhibited bactericidal efficacy against methicillin-resistant S. aureus and its high tolerance phenotypes like intracellular bacteria and persister cells without inducing resistance. Critically, sub-minimal inhibitory concentrations (sub-MICs) of Visomitin could serve as a potent quorum-quencher reducing virulence production (such as haemolysin and staphyloxanthin), along with inhibiting biofilm formation, self-aggregation, and colony spreading of S. aureus. These effects were probably mediated by interfering with the S. aureus accessory gene regulator quorum sensing system. In summary, our findings suggest that Visomitin shows dual antimicrobial effects, including bactericidal effects at the concentrations above MIC and quorum sensing inhibition effects at sub-MICs, which holds promise for treating MRSA-related refractory infections.


  • Insights into the antimicrobial effects of tafenoquine against Enterococcus and its biofilms

    by Yuan Wu, Huilong Li, Pingyun Wu, Ruolan Wu, Pengfei She

    The purpose of this study is to assess the in vitro antimicrobial and anti-biofilm effects of the anti-protozoal agent tafenoquine (TAF) on Enterococcus and elucidate its underlying mode of action. The present work investigated the susceptibility of TAF on 3 type strains and 11 clinical isolates of enterococci. The results indicated that TAF exhibited powerful antimicrobial activity against both of Enterococcus faecalis and Enterococcus faecium with minimum inhibitory and bactericidal concentrations ranging from 8 to 16 µg ml−1. Meanwhile, biofilm inhibition and eradication assays showed that TAF exhibited potent anti-biofilm activity against E. faecalis ATCC 29212 and E. faecium ATCC 19434. Ultra-microscopic observations revealed significant changes in bacterial morphology and structure caused by TAF, particularly for the disruption of plasma membrane. Mechanistic investigations also revealed that TAF altered both membrane permeability and potential while also impacting adenosine triphosphate production as well as reactive oxygen species generation. In addition, no detectable cytotoxicity of TAF on human cells was observed at concentrations near the minimal inhibitory concentration. In summary, this study confirmed that TAF could effectively inhibit Enterococcus as well as its biofilm formation.


  • 西咪匹韦对表皮葡萄球菌及其生物膜的体外抑制作用

    by Yingjia Li, Chaoni Cai, Zixin Liu, Xichang Tang, Lin Qu, Yuan Wu, Pingyun Wu, Yao Duan, Pengfei She

    表皮葡萄球菌是一种常引起院内感染的革兰阳性氏条件致病菌。抗生素的不合理使用导致其耐药性逐渐增高,药物再利用已成为难治性耐药菌感染治疗的研究热点。本研究拟探讨抗病毒性肝炎药物西咪匹韦对表皮葡萄球菌及其生物膜的体外抑制作用。 通过微量肉汤稀释实验检测西咪匹韦对表皮葡萄球菌的最低抑菌浓度(minimal inhibitory concentration,MIC)和最低杀菌浓度(minimal bactericidal concentration,MBC);采用结晶紫染色检测西咪匹韦对表皮葡萄球菌生物膜形成的抑制作用;SYTO9/PI双荧光染色检测西咪匹韦对表皮葡萄球菌及其生物膜内活菌的杀菌作用;棋盘稀释实验检测西咪匹韦联用庆大霉素的抗菌活性,并通过绘制时间-抑菌曲线进一步验证其协同抗菌活性。 西咪匹韦对表皮葡萄球菌具有明显的抗菌活性,其对标准菌株和临床菌株的MIC和MBC分别为2~16 μg/mL和4~32 μg/mL。SYTO9/PI荧光染色进一步证明西咪匹韦对表皮葡萄球菌的杀菌作用。4 μg/mL的西咪匹韦可显著减少表皮葡萄球菌盖玻片上生物膜的形成并破坏生物膜的正常结构。MIC的西咪匹韦还可抑制TSB肉汤中导尿管表面表皮葡萄球菌的黏附作用,使黏附量从0.700±0.020减少到0.050±0.004(t=54.03,Pt=82.78,P<0.001)。此外,西咪匹韦与庆大霉素联用还具有明显的协同抗菌作用,其协同抑菌指数为0.5。 西咪匹韦对表皮葡萄球菌具有显著的抗菌作用,且能有效抑制其生物膜的形成。


  • [Perifosine inhibits biofilm formation of Pseudomonas aeruginosa by interacting with PqsE protein].

    by P F She, L L Xu, Y Q Liu, Z H Li, S S Liu, Y M Li, L Y Zhou, Y Wu

    To explore the biofilm inhibitory efficacy of perifosine against Pseudomonas aeruginosa (P. aeruginos) and its mechanisms. Twenty-fourwell plate was used to form biofilms at the bottom and crystal violet staining was used to determine the biofilm inhibitory effects of perifosine against P. aeruginosa, the wells without perifosine was set as control group. Glass tubes combined with crystal violet staining was used to detect the gas-liqud interface related bioiflm inhibitory effects of perifosine, the wells without perifosine was set as control group. Time-growth curved was used to detect the effects of perifosine on the bacteial planktonic cells growth of P. aeruginosa, the wells without perifosine was set as control group. The interaction model between perifosine and PqsE was assessed by molecular docking assay. The inhibitory effects of perifosine on the catalytic activity of PqsE was determined by detection the production of thiols, the wells without perifosine was set as control group. Binding affinity between perifosine and PqsE was detected by plasma surface resonance. The biofims at the bottom of the microplates and air-liquid interface were effectively inhibited by perifosine at the concentration of 4-8 μg/ml. There was no influence of perifosine on the cells growth of P. aeruginosa. The resuts of molecular docking assay indicates that perifosine could interacted with PqsE with the docking score of -10.67 kcal/mol. Perifosine could inhibit the catalytic activity of PqsE in a dose-dependent manner. The binding affinity between perifosine and PqsE was comfirmed by plasma surface resonance with KD of 6.65×10-5mol/L. Perifosine could inhibited the biofilm formation of P. aeruginosa by interacting with PqsE.

  • Open Access

    Corrigendum: Synergistic Microbicidal Effect of Auranofin and Antibiotics Against Planktonic and Biofilm-Encased S. aureus and E. faecalis

    by Pengfei She, Linying Zhou, Shijia Li, Yiqing Liu, Lanlan Xu, Lihua Chen, Zhen Luo, Yong Wu

    Corrigendum: Synergistic Microbicidal Effect of Auranofin and Antibiotics Against Planktonic and Biofilm-Encased S. aureus and E. faecalis